Concentrix (NASDAQ:CNXC) Shares Gap Down – Should You Sell?

Concentrix Corporation (NASDAQ:CNXC) gapped down prior to trading on Tuesday . The stock had previously closed at $40.48, but opened at $38.30. Concentrix shares last traded at $40.1540, with a volume of 951,674 shares traded.

More Concentrix News

Here are the key news stories impacting Concentrix this week:

• Positive Sentiment: Record cash generation and shareholder returns: Concentrix reported record operating cash flow ($807M for FY2025) and adjusted free cash flow ($626M) and returned $258M to shareholders via dividends and buybacks, supporting cash‑flow credibility and capital allocation. Quiver: Concentrix Q4/FY2025 Results
• Positive Sentiment: Earnings and revenue slightly beat expectations: Non‑GAAP diluted EPS of $2.95 beat consensus by $0.02 and revenue of ~$2.55B modestly topped estimates, showing underlying operational resilience. MarketBeat: Concentrix Earnings
• Positive Sentiment: Management issued explicit quarterly and full‑year non‑GAAP EPS guidance (Q1: $2.57–2.69; FY: $11.48–12.07) and revenue targets, reinforcing a path to improved free cash flow (~$630M–$650M for FY2026). That forward framework gives investors a clearer earnings runway. GlobeNewswire: Concentrix Results & Guidance
• Positive Sentiment: Analyst support: Recent analyst coverage includes reaffirmations and price targets (e.g., Barrington’s $62 target), which could support demand if management hits guidance. Quiver: Analyst Ratings & Targets
• Neutral Sentiment: Non‑GAAP metrics softened vs. prior year: Non‑GAAP diluted EPS fell to $2.95 from $3.26 (‑9.5%), and adjusted EBITDA/operating margins narrowed modestly — signaling demand and margin pressure even as revenue grew. GlobeNewswire: Non‑GAAP Results
• Negative Sentiment: Large non‑cash goodwill impairment: The company recorded a $1.523B goodwill impairment in Q4, producing a GAAP operating loss (~$1.38B) and massive GAAP EPS loss — a headline item that weighs on investor confidence and valuation. GlobeNewswire: Impairment Disclosure
• Negative Sentiment: Market/technical pressure and valuation questions: CNXC remains below its 200‑day average and well under recent 1‑year highs, and the impairment highlights sensitivity of GAAP metrics and share price — factors likely contributing to today’s share weakness.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Robert W. Baird decreased their target price on Concentrix from $75.00 to $62.00 and set an “outperform” rating on the stock in a report on Monday, September 29th. Canaccord Genuity Group reissued a “buy” rating and set a $80.00 target price on shares of Concentrix in a research report on Tuesday, September 23rd. Barrington Research restated an “outperform” rating and issued a $62.00 price target on shares of Concentrix in a research report on Monday. Wall Street Zen raised shares of Concentrix from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Finally, Weiss Ratings upgraded Concentrix from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Concentrix has a consensus rating of “Moderate Buy” and a consensus target price of $66.25.

Concentrix Stock Performance

The stock has a 50 day moving average price of $38.43 and a two-hundred day moving average price of $46.77. The company has a market cap of $2.49 billion, a P/E ratio of 8.39, a price-to-earnings-growth ratio of 0.59 and a beta of 0.48. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 1.10.

Concentrix (NASDAQ:CNXC) last posted its quarterly earnings results on Tuesday, January 13th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.02. The business had revenue of $2.55 billion for the quarter, compared to analyst estimates of $2.54 billion. Concentrix had a net margin of 3.25% and a return on equity of 16.02%. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the business posted $3.26 EPS. Concentrix has set its Q1 2026 guidance at 2.570-2.690 EPS and its FY 2026 guidance at 11.480-12.070 EPS. On average, research analysts predict that Concentrix Corporation will post 10.11 earnings per share for the current fiscal year.

Insider Activity at Concentrix

In other news, CEO Christopher A. Caldwell bought 2,000 shares of the stock in a transaction that occurred on Thursday, October 30th. The stock was acquired at an average price of $42.03 per share, with a total value of $84,060.00. Following the completion of the purchase, the chief executive officer directly owned 286,661 shares of the company’s stock, valued at approximately $12,048,361.83. This represents a 0.70% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 3.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Concentrix

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Osaic Holdings Inc. grew its holdings in shares of Concentrix by 13.4% in the second quarter. Osaic Holdings Inc. now owns 2,222 shares of the company’s stock valued at $118,000 after acquiring an additional 263 shares in the last quarter. Earned Wealth Advisors LLC grew its position in shares of Concentrix by 6.4% during the 2nd quarter. Earned Wealth Advisors LLC now owns 4,488 shares of the company’s stock valued at $237,000 after purchasing an additional 269 shares in the last quarter. True Wealth Design LLC raised its holdings in shares of Concentrix by 39.3% in the 2nd quarter. True Wealth Design LLC now owns 1,163 shares of the company’s stock valued at $61,000 after acquiring an additional 328 shares in the last quarter. Clearstead Advisors LLC lifted its position in Concentrix by 26.4% during the third quarter. Clearstead Advisors LLC now owns 1,650 shares of the company’s stock valued at $76,000 after purchasing an additional 345 shares during the last quarter. Finally, Parkside Financial Bank & Trust grew its position in Concentrix by 23.9% in the second quarter. Parkside Financial Bank & Trust now owns 1,818 shares of the company’s stock worth $96,000 after acquiring an additional 351 shares in the last quarter. Institutional investors own 90.34% of the company’s stock.

About Concentrix

Concentrix Inc (NASDAQ: CNXC) is a global business services company specializing in customer engagement solutions and technology‐driven business process outsourcing. The firm’s offerings encompass customer care delivered across voice and digital channels, back‐office processing, analytics and consulting, and automated workflow management. By integrating proprietary platforms, strategic partnerships and advanced automation, Concentrix helps clients enhance customer experiences and streamline operations.

Its capabilities extend to digital marketing and technology implementation, leveraging artificial intelligence, machine learning and data analytics to optimize customer journeys.